Understand the source comparison
Tesofensine vs Research Peptides: Side Effect and Tolerability Profiles
Tesofensine Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin) Dry mouth (40%), insomnia (28%), elevated heart rate (+5 bpm mean), headache 24–48 hours for appetite suppression Contraindicated with uncontrolled hypertension; requires ba
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine
- Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin)
- Dry mouth (40%), insomnia (28%), elevated heart rate (+5 bpm mean), headache
- 24–48 hours for appetite suppression
- Contraindicated with uncontrolled hypertension; requires baseline and periodic cardiovascular monitoring
- GLP-1 Agonists (semaglutide, tirzepatide)
- GLP-1 receptor agonism → delayed gastric emptying, enhanced satiety signaling
- Nausea (30–45%), vomiting, diarrhea, constipation. Peaks during dose titration
- 4–8 weeks for full appetite suppression at therapeutic dose
- Cardiovascular risk reduction demonstrated in MACE trials; generally cardioprotective
- Growth Hormone Peptides (GHRP-2, ipamorelin, CJC-1295)
- Ghrelin receptor agonism → increased endogenous GH secretion
- Joint discomfort, water retention, transient hyperglycemia (fasting), increased appetite (GHRP-6 specifically)
- 2–4 weeks for metabolic shift; no acute appetite effect
- Minimal direct cardiovascular impact; glucose monitoring advised in insulin-resistant individuals
- Metabolic Peptides (AOD-9604, MOTS-c)
- Lipolysis stimulation (AOD) or mitochondrial function enhancement (MOTS-c)
- Minimal reported. Occasional injection site irritation
- Gradual over 4–8 weeks; no acute appetite or energy effect
- No significant cardiovascular concerns in published literature
- Professional Assessment
- Tesofensine produces the fastest appetite suppression but requires cardiovascular clearance. GLP-1 agonists are slower but better tolerated long-term. GH peptides and metabolic modulators support body composition without appetite suppression. Stacking requires dose reduction and monitoring.
- The critical distinction: tesofensine's stimulant-like profile (elevated heart rate, insomnia, dry mouth) mirrors sympathomimetic compounds, which makes it unsuitable for individuals with cardiovascular contraindications. GLP-1 agonists carry GI side effects but are cardiovascular-neutral or protective. The SUSTAIN-6 and SELECT trials demonstrated reduced major adverse cardiovascular events (MACE) with semaglutide. Growth hormone peptides and metabolic modulators are generally well-tolerated but don't produce acute appetite or energy changes, limiting their utility as standalone fat-loss agents. In our experience, researchers using tesofensine must screen for hypertension, tachycardia, and psychiatric contraindications before initiation. A requirement not typically applied to peptide protocols.